Insmed Announces Initiation of Phase II Clinical Trial with IPLEX(TM) in Myotonic Muscular Dystrophy
Promising Results Observed in Ongoing Open Label Trial
07-Nov-2007 -
Insmed Inc., a biopharmaceutical company focused on the development and approval of drugs for the treatment of metabolic diseases with unmet medical needs, announced the planned initiation of a 24-week, multi-center, randomized, double blind, placebo-controlled Phase II clinical trial with ...
clinical trials
metabolic diseases
myotonic muscular dystrophy
+1